Fig. 3From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP studyProgression-free survival (a) and overall survival (b) in patient subgroups based on their EGFR mutation statusBack to article page